Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Avanafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avanafil SCHEMBL29372265 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL16377474 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL30446867 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL31143663 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL1171811 | 1.00 | PDE5A (1.00) | PDE5A | |
| Avanafil SCHEMBL30335524 | 1.00 | PDE5A (1.00) | PDE5A | |
| SCHEMBL29144167 | 0.97 | PDE5A (0.94) | PDE5A | |
| Avanafil SCHEMBL28462779 | 0.96 | PDE5A (0.92) | PDE5A | |
| Avanafil SCHEMBL28462777 | 0.96 | PDE5A (0.92) | PDE5A | |
| SCHEMBL28723744 | 0.95 | PDE5A (0.90) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5595 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | AMGEN INC. (US) | 2026-05-28 | — | — | US | claimed |
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3784317-B1 | ACCESSORY APPARATUS FOR AN INHALER | MANNKIND CORP (US) | 2026-03-18 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4687904-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH MITOCHONDRIAL COMPLEX IV DEFICIENCY | Charité - Universitätsmedizin Berlin (DE) | 2026-02-11 | — | — | EP | claimed |
| US-20260021100-A1 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | ARIBIO CO LTD (KR) | 2026-01-22 | — | — | US | claimed |
| EP-4665351-A1 | IMPROVING GLYMPHATIC-LYMPHATIC EFFLUX | University of Rochester (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4656194-A1 | COMPOSITION FOR PREVENTING OR TREATING POST-TRAUMATIC STRESS DISORDER, COMPRISING PHOSPHODIESTERASE TYPE 5 INHIBITOR AS ACTIVE INGREDIENT | Aribio Co., Ltd (KR) | 2025-12-03 | — | — | EP | claimed |
| US-20250352518-A1 | A BENZIMIDAZOLE COMPOUND WITH ANTIHELMINTHIC ACTIVITY FOR USE IN REVERSING, ARRESTING OR SLOWING DOWN CELLULAR AGEING IN A VERTEBRATE SUBJECT | RAVAN BIO LIMITED (GB) | 2025-11-20 | — | — | US | claimed |
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | claimed |
| EP-1366760-A1 | TABLETS QUICKLY DISINTEGRATED IN ORAL CAVITY | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-03 | — | — | EP | claimed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | claimed |
| US-20030195220-A1 | A tablet has an acid, with reduced solubility in the neutral and alkaline regions, is used for treating sexual disorders erectile dysfunction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-10-16 | — | — | US | claimed |
| EP-1316316-A1 | PREPARATIONS FOR ORAL ADMINISTRATION | TANABE SEIYAKU CO., LTD. (JP) | 2003-06-04 | — | — | EP | claimed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | claimed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |